NCT03763162 2026-04-15
Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
Clinical Trials
10 trialsNCT04847453 2026-04-13
Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT03173092 2026-03-18
A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)
Takeda
Phase 4 Active not recruiting
NCT02339922 2026-03-05
Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma
University of Washington
Phase 2 Active not recruiting
NCT03506373 2026-03-05
Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia
Mayo Clinic
Phase 2 Terminated
NCT04094961 2026-03-05
Ixazomib + Pomalidomide + Dexamethasone In MM
Dana-Farber Cancer Institute
Phase 1/2 Active not recruiting
NCT03283917 2026-02-27
Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT04305691 2026-02-27
Trial of Ixazomib for Kaposi Sarcoma
AIDS Malignancy Consortium
Phase 2 Recruiting
NCT04463953 2026-02-11
Zanubrutinib, Ixazomib and Dexamethasone in Patients With Treatment Naive Waldenstrom's Macroglobulinemia
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Completed
NCT02389517 2026-01-22
Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant
University of Chicago
Phase 2 Completed